01.12.2012 Views

View - ResearchSpace@Auckland - The University of Auckland

View - ResearchSpace@Auckland - The University of Auckland

View - ResearchSpace@Auckland - The University of Auckland

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Colom et al.20O4; Guilbert, Morgan et aL.2006). Side effects noted were growth velocity<br />

(Guilbert, Morgan et al. 2006), adrenal suppression, increased cough and hoarseness, and<br />

cataract formation (Bisgaard, Allen et al. 2004). An earlier Cochrane review in 2000 had<br />

suggested that episodic high dose IHCS was partially effective. However, they concluded that<br />

"there is no current evidence to favour maintenance low dose IHCS in the prevention and<br />

management <strong>of</strong> episodic mild viral wheeze <strong>of</strong> childhood" (McKean and Ducharme). In<br />

addition, more recent Cochrane reviews do not support the use <strong>of</strong> IHCS in acute bronchiolitis<br />

or used to prevent wheezing post acute illness in 2006 (Blom, Ermers et al.) or the use <strong>of</strong> oral<br />

steroids for bronchiolitis in 2004 (Patel, Platt et al.). So while at the current time steroids are<br />

not recommended in this age group, the increased use exposes many more children to<br />

corticosteroid therapy, <strong>of</strong>ten before a definitive diagnosis <strong>of</strong> classic asthma is able to be made<br />

(de Blic and Scheinmann 2000).<br />

In fact it is interesting to note within the guidelines, the significant difference in the level <strong>of</strong><br />

evidence available for the different age groups. For example in the pharmacological<br />

management chapter <strong>of</strong> the SIGN guidelines (SIGN 2005), the graded evidence for the<br />

recommendations is presented in age brackets (>12 years and adults, 5-12 years and < 5<br />

years). Across these age groups the evidence frequently drops from '1++' (strong evidence<br />

with high quality meta-analyses and systematic reviews <strong>of</strong> randomised controlled trials) down<br />

to '4' (expert opinion) in the youngest age group.<br />

1.5.2 A marker for inflammation would be usefuI<br />

<strong>The</strong>re is a need to minimize side effects, while preventing morbidity (and mortality). This is<br />

important for better individual health, and is also important financially - reducing work and<br />

school days lost. Other financial burdens can be experienced by a family with a child with<br />

uncontrolled asthma as revealed in this quote taken from the 'Trying to Catch Our Breath,<br />

monograph (Anonymous 2006) :<br />

"I visited a family who had almost no furniture in the house. <strong>The</strong>y had taken their child<br />

to the doctor one evening in the previous week for an asthma attack. <strong>The</strong>y spent $80 for<br />

the visit and the medications. This was their entire food budget for the following week.<br />

<strong>The</strong>y were eating white bread and butter." (Claire Richards, Asthma Nurse Educator,<br />

Porirua Asthma Service, New Zealand)<br />

In 2005, the GINA guideline (GINA 2005) suggested to "titrate the dose <strong>of</strong> inhaled<br />

corticosteroid to the lowest dose at which effective control <strong>of</strong> asthma is maintained". <strong>The</strong><br />

23

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!